FIGURE 2.
Survival outcomes of metastatic renal cell carcinoma patients treated with SBRT combined with TKI (N=56). A, Overall survival. B, Progression-free survival. C, Local progression-free survival. D, Distant progression-free survival of all patients. Overall survival (E) and progression-free survival of patients who achieved local CR and non-CR after SBRT (F). CR indicates complete response; SBRT, stereotactic body radiotherapy; TKI, tyrosine kinase inhibitors.